Detalles de la búsqueda
1.
Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.
J Infect Dis
; 215(8): 1255-1263, 2017 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28329190
2.
Immune-correlates analysis of an HIV-1 vaccine efficacy trial.
N Engl J Med
; 366(14): 1275-86, 2012 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-22475592
3.
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.
J Infect Dis
; 206(3): 431-41, 2012 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22634875
4.
Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations.
PLoS One
; 13(4): e0196397, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29702672
5.
Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens.
AIDS Res Hum Retroviruses
; 33(5): 410-423, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28006952
6.
IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens.
AIDS Res Hum Retroviruses
; 31(11): 1178-86, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26234467
7.
Enhanced sensitivity of detection of cytotoxic T lymphocyte responses to HIV type 1 proteins using an extended in vitro stimulation period for measuring effector function in volunteers enrolled in an ALVAC-HIV phase I/II prime boost vaccine trial in Thailand.
AIDS Res Hum Retroviruses
; 20(6): 642-4, 2004 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-15242541
8.
HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/E.
Vaccine
; 30(5): 832-6, 2012 Jan 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-22085554
9.
A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.
J Acquir Immune Defic Syndr
; 46(1): 48-55, 2007 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17909315
10.
Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans.
Vaccine
; 25(45): 7737-42, 2007 Nov 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-17920731
11.
Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand.
Vaccine
; 23(19): 2522-9, 2005 Mar 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-15752839
12.
Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.
J Infect Dis
; 190(4): 702-6, 2004 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-15272397
Resultados
1 -
12
de 12
1
Próxima >
>>